Neurocrine Biosciences, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $1.88 | $2.36 | +25.5% | Beat |
| Q12026 FY2026 | $1.28 | $1.41 | +10.2% | Beat |
| Q42025 FY2025 | $1.78 | $1.43 | -19.7% | Miss |
Back to NBIX overview · NBIX holders · NBIX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.